Increased risk for cerebral ischemic stroke in diabetes: genetically polymorphic CYP mediated production of neuroprotective EETs and sulfonylurea metabolism in relation with KATP channels  

作　　者：Umit Yasar Melih 0. Babaoglu 

机构地区：[1]Department of Medical Pharmacology, Hacettepe University, Faculty of Medicine, Ankara, Turkey

出　　处：《Acta Pharmacologica Sinica》2019年第4期569-570,共2页中国药理学报（英文版）

摘　　要：Dear Editor, Szeto et al. thoroughly reviewed the role of ATP sensitive potassium (KATP) channels in cerebral ischemic stroke and diabetes in a recent article [1]. KAtp channels are expressed in many organs, such as brain, heart, and pancreas. Recent studies dem on strated the protective role of these cha nnels in cardiac pathologies and ischemia of brain [1]. Diabetic patients are often prescribed with sulfonyI urea oral antidiabetics, for which the mechanism of action is inhibition of KATP channels and thereby, in creased excretion of in suli n by pan creatic islet cells. Tolbutamide, glyburide, glibenclamide, glipizide, gliclazide, and glimepiride are among sulfonylureas that are mainly metabolized by cytochrome P450 (CYP) 2C9 [2, 3]. Meglitinides are another group of frequently used oral antidiabetics. Nateglinide and repaglinide are members of this newer group. They stimulate insulin release by partly acting on KATP channels and this group of drugs are also partly metabolized by CYP2C9 and 2C8 [3].

关 键 词：INCREASED RISK CEREBRAL ischemic stroke KATP channels 

分 类 号：R[医药卫生]